Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy
Authors
Keywords
-
Journal
LEUKEMIA
Volume 31, Issue 4, Pages 872-881
Publisher
Springer Nature
Online
2016-10-14
DOI
10.1038/leu.2016.282
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents
- (2016) Jane Merlevede et al. Nature Communications
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia
- (2015) Jeffery M. Klco et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Leukemia-Associated Somatic Mutations Drive Distinct Patterns of Age-Related Clonal Hemopoiesis
- (2015) Thomas McKerrell et al. Cell Reports
- TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
- (2014) R. Bejar et al. BLOOD
- Age-related mutations associated with clonal hematopoietic expansion and malignancies
- (2014) Mingchao Xie et al. NATURE MEDICINE
- Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
- (2014) Giulio Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
- (2014) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and biological implications of driver mutations in myelodysplastic syndromes
- (2013) E. Papaemmanuil et al. BLOOD
- A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial
- (2013) S. D. Gore et al. HAEMATOLOGICA
- Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma
- (2013) Jesús F. San-Miguel et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
- (2013) F Traina et al. LEUKEMIA
- Clonal diversity of recurrently mutated genes in myelodysplastic syndromes
- (2013) M J Walter et al. LEUKEMIA
- Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
- (2013) T Haferlach et al. LEUKEMIA
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations
- (2012) B. Will et al. BLOOD
- The Origin and Evolution of Mutations in Acute Myeloid Leukemia
- (2012) John S. Welch et al. CELL
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
- (2012) C Craddock et al. LEUKEMIA
- A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission
- (2012) Y Boumber et al. LEUKEMIA
- Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
- (2012) Li Ding et al. NATURE
- Clonal Architecture of Secondary Acute Myeloid Leukemia
- (2012) Matthew J. Walter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes
- (2011) Lewis R. Silverman et al. CANCER
- Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
- (2011) Michael Lübbert et al. JOURNAL OF CLINICAL ONCOLOGY
- DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
- (2011) K H Metzeler et al. LEUKEMIA
- Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
- (2011) R Itzykson et al. LEUKEMIA
- Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
- (2009) Peter Atadja CANCER LETTERS
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
- (2009) Pierre Fenaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia
- (2009) Amanda F. Cashen et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now